TELA Bio (TELA) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached a record $19.0 million, up 26% year-over-year, driven by strong demand for OviTex and OviTex PRS and international expansion.

• Net loss narrowed to $10.4 million from $11.0 million in Q3 2023, aided by a $7.6 million gain from the sale of the NIVIS product line.

• Over 700 hospitals globally use the products, and a public offering added $43–$46 million in cash, supporting future growth and profitability.

• Operational efficiency improvements and cost-cutting measures are expected to reduce 2025 operating expenses by $5–$10 million.

• 2024 revenue guidance reaffirmed at $74.5–$76.5 million, representing 27–31% annual growth.

Financial highlights

• Q3 2024 revenue: $19.0 million (+26% year-over-year); gross profit: $12.9 million (68% margin).

• Net loss: $10.4 million in Q3 2024; operating loss: $9.4 million.

• Cash and cash equivalents at quarter-end: $17.3 million, with $43–$46 million raised in a public offering post-Q3.

• Operating expenses rose to $22.2 million, mainly due to higher compensation and severance.

• Nine-month revenue: $51.7 million, up from $41.5 million in the prior year.

Outlook and guidance

• Full-year 2024 revenue expected at $74.5–$76.5 million, up 27–31% year-over-year.

• Operating and net losses expected to be lower in 2024 than 2023, excluding divestiture impacts.

• OpEx reductions of $5–$10 million annually expected to be fully realized in 2025.

• Existing cash resources, including public offering proceeds, expected to fund operations for at least 12 months.

• Monitoring for potential impacts from IV fluid shortages and natural disasters, but no material effect detected yet.